A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2)

What Was Tested

The paper reports a study of Insulin Detemir and NPH Insulin (isophane), published as a randomized controlled trial.

This randomized, open-label, phase 3 trial recruited patients (n = 42) aged 10-17 years diagnosed with T2D already receiving metformin ± other oral antidiabetic drugs ± basal insulin.

The rate of symptomatic blood glucose-confirmed hypoglycemic episodes was 0.4 episodes/patient-year of exposure (PYE) for insulin detemir vs. 1.1 episodes/PYE for NPH insulin.

Who Took Part

According to the abstract, 3 patients were involved.

By PubMed's age tags, the people studied were children and teenagers, both men and women.

How the Study Was Run

In design terms this was a randomized and open-label study.

The patients were allocated by chance, so the Insulin Detemir group and the comparison group should start out alike.

Being open-label, the Insulin Detemir study did not mask who received what.

The timeline in the abstract includes 26 weeks.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Insulin Detemir, Insulin, Isophane and Life Style.

Author keywords: Adolescents, Children, NPH insulin and Type 2 diabetes.

What This Means in Plain Language

The paper is a randomized and open-label study of Insulin Detemir and NPH Insulin (isophane) in 3 patients over 26 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (European journal of pediatrics), a journal based in Germany.

More context: the Insulin Detemir compound page and the NPH Insulin (isophane) compound page.